Approach to enhance human antibody expression in plant cells

以植物为基础生产高价值的治疗性蛋白，如单抗，为哺乳动物细胞系统中的蛋白质表达提供了一种有吸引力的替代方案。PlantForm Corporation是一家成立已久的加拿大公司，正在支持卡尔加里大学道格拉斯·芒奇博士的实验室进行旨在提供一种增强的蛋白质表达技术的研究，该技术可普遍应用于任何感兴趣的高价值蛋白质的表达。PlantForm最先进的产品之一是乳腺癌治疗抗体。这笔赠款将支持一项新的合作研究项目，该项目将测试一种新的RNA结合蛋白与翻译增强子偶联可以在植物细胞系统中特异性地提高这种抗体的表达这一假设。卡尔加里大学的缪奇实验室最近从模式植物拟南芥中鉴定了一种序列特异的高亲和力RNA结合蛋白(APUM23)。当与翻译增强剂偶联时，APUM23有可能显著增加这种治疗性抗体的合成。该项目的成功将为PlantForm带来可观的收入或成本节约，并将进一步确立该公司在治疗蛋白植物表达领域的行业领先地位。

Plant-based production of high-value therapeutic proteins, such as monoclonal antibodies, provides anattractive alternative to protein expression in mammalian cell systems. PlantForm Corporation is an establishedCanadian company that is supporting the lab of Dr. Douglas Muench at the University of Calgary on studiesaimed at delivering an enhanced protein expression technology that can be universally applied to the expressionof any high value protein of interest. One of PlantForm's most advanced products is a breast cancer therapeuticantibody. This grant will support a new collaborative research project that will test the hypothesis that a novelRNA-binding protein coupled to a translational enhancer can specifically elevate the expression of thisantibody in a plant cell system. The Muench lab at the University of Calgary has recently characterized asequence specific, high affinity RNA-binding protein (APUM23) from the model plant Arabidopsis. Whencoupled to a translational enhancer, APUM23 has the potential to significantly increase the synthesis of thistherapeutic antibody. Success with this project will result in substantial revenue generation or cost savings toPlantForm, and will further establish the company as an industry leader in plant expression of therapeuticproteins.